# RayzeBio (BMS)

Source: https://nuclide.cc/companies/rayzebio/  
Nuclide record `rayzebio` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

RayzeBio is the actinium-225 radiopharma company that BMS bought for $4.1B; its RYZ101 is in phase 3.

## Summary

RayzeBio, based in San Diego, is the actinium-225 radiopharmaceutical company that Bristol Myers Squibb bought for 4.1 billion dollars, and its RYZ101 is in phase 3. RYZ101 is actinium-225 DOTATATE for somatostatin-receptor-positive neuroendocrine tumours, RYZ801 is an actinium-225 PSMA agent, and the company built in-house actinium-225 manufacturing. Nuclide links it to neuroendocrine tumours, to peptide receptor radionuclide therapy and targeted alpha therapy, to the actinium-225 DOTATATE drug record, and to the radiopharmaceutical roadmap from iodine through lutetium to actinium. Whether an alpha emitter can improve on lutetium-based radioligand therapy is the question RYZ101's phase 3 will answer. Actinium-225 DOTATATE has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: San Diego, CA
- Type: radiopharma
- Website: https://www.rayzebio.com

## Sources

- Official website: https://www.rayzebio.com

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/)
- drugs: [Actinium-225 DOTATATE](https://nuclide.cc/drugs/ryz101/)
- trials: [Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC](https://nuclide.cc/trials/nct06726161/), [Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.](https://nuclide.cc/trials/nct06590857/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://nuclide.cc/technologies/actinium-225-supply/), [Peptide receptor radionuclide therapy (PRRT)](https://nuclide.cc/technologies/prrt/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/)
- roadmaps: [Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline](https://nuclide.cc/roadmaps/alpha-therapy-roadmap/), [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://nuclide.cc/roadmaps/radiopharma-roadmap/)
- bottlenecks: [Actinium-225 supply](https://nuclide.cc/bottlenecks/b-ac225-supply/), [Clinical trial capacity for radioligand therapy](https://nuclide.cc/bottlenecks/b-rlt-trial-capacity/)
- fronts: [Targeted alpha therapy](https://nuclide.cc/fronts/f-alpha-therapy/)

---
JSON: https://nuclide.cc/api/v1/entities/rayzebio.json